StockTipsArenaBeta

BUY Piramal Pharma Limited — Pradip Hotchandani, Prudent Corporate Advisory Services

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))28 Aug 2026via CNBC Awaaz.

Entry₹218.76Inferred
Target₹250
Total upside +14.28% (call closed)
Stop loss₹211-3.55% risk
Exit₹2111 Sept 2026, 10:35 am
Stop-loss hit-3.55%
Follow Pradip Hotchandani for new calls(20% target hit, 41 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Sept 2026
7 supporting2 neutral2 opposing
Supports the BUY call (7)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 4d ago

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 5d ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · 5d ago

Yapan Bio to become Piramal subsidiary following acquisition

NewsGoogle News·20 Aug · 2w ago

(opens in new tab)

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

NewsGoogle News·19 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (2)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 4d ago

(opens in new tab)

Piramal Pharma emphasises sustainability in FY 2025-26 report

NewsGoogle News·24 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (2)

Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26

NewsGoogle News·24 Aug · 1w ago

(opens in new tab)

Piramal Pharma block deal likely cancelled; stock falls 3%

NewsCnbc-Tv18·14 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Pradip Hotchandani, Prudent Corporate Advisory Services

Every call and its outcome